Condition
Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Amg 162 180 Mg Sc Q 12 Weeks
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Amg 162 180 Mg Sc Q 12 Weeks1
- Amg 1621
- Iv Bisphosphonate Q 4 Weeks1
- Amg 162 180 Mg Q 4 Weeks1
Active Sponsors
- Amgen2
Related Conditions
- Bone Metastases In Men With Hormonerefractory Prostate Cancer2
- Bone Metastases In Subjects With Advanced Breast Cancer2